ArticleFrontiers in pediatrics2025
Prognostic value of blood inflammatory composite markers in the survival of pediatric patients with secondary hemophagocytic lymphohistiocytosis.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the prognostic value of blood inflammatory composite markers in the survival of pediatric patients diagnosed with secondary hemophagocytic lymphohistiocytosis (sHLH). Methods: Clinical data from 138 newly diagnosed sHLH patients hospitalized between January 2012 and October 2023 were analyzed. Receiver operating characteristic curve analysis was used to determine cutoff values and evaluate predictive accuracy, while Cox regression analysis was employed to identify prognostic factors. Results: The median age of the 138 sHLH patients was 38 months, with a female-to-male ratio of 0.92. Infection was identified as the most common cause of sHLH, 52.9% testing positive for the epstein-barr virus (EBV). Clinical features included decreased blood cell counts in 87.0% of patients, hypofibrinogenemia in 55.07%, hypertriglyceridemia in 46.38%, and elevated ferritin levels in 94.2%. Additionally, all patients experienced fever, while hepatomegaly and splenomegaly were observed in 66.67% and 76.81%, respectively. During the study, 48 patients died. Cox regression analysis identified red blood cell distribution width (RDW) ≥14.35%, fibrinogen <1.5 g/L, red blood cell distribution width to platelet ratio (RPR) ≥0.36, and lactate dehydrogenase to serum albumin ratio (LAR) ≥56.02 as significant predictors of decreased survival. Conclusion: This study provides preliminary evidence that accessible inflammatory markers like LAR and RPR may assist in early prognostic assessment of pediatric sHLH. These findings highlight the potential utility of routine blood parameters, warranting further validation in larger, stratified cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.